Indeed, CD90+ fibroblast and FAP+ fibroblast counts are significantly positively associated with progression-free survival (PFS) and overall survival (OS), whereas a-SMA+ fibroblast count is negatively associated with PFS and OS in melanoma patients treated with anti-PD1 Abs monotherapy [100]. Here, SMN1 is linked to melanoma.